Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live
Entities / United States — Food and Drug Administration / Eisai

United States — Food and Drug Administration & Eisai

3 shared events · Importance 4 · Last updated Jun 03, 2026

Importance
4
Shared Events
3
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
Shared Events (3)
17
Business
Grey Matters receives PET scanner
United States — Food and Drug Administration: The United States — Food and Drug Administration has cleared the CareMiBrain system for use and has approved new monoclonal antibody treatments for Alzheimer's Disease, creating a market for the PET scans.
Eisai: Eisai, in collaboration with Biogen, developed Leqembi, one of the FDA-approved monoclonal antibody treatments for Alzheimer's Disease, which requires a positive beta-amyloid brain scan.
Jul 06, 2026 · 6 articles
0
Business
Eisai Projects Leqembi Revenue Growth
May 15, 2026 · 6 articles
0
Regulatory
Leqembi Iqlik PDUFA Date Extended
May 08, 2026 · 14 articles
NEWSDESK
Explore this relationship live

Track how United States — Food and Drug Administration and Eisai interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.